RCT: No benefit of Apolipoprotein A1 infusions in preventing cardiovascular events post-myocardial infarction

This international, double-blind, placebo-controlled trial investigated the effect of apolipoprotein A1 (CSL112) infusions on cardiovascular outcomes in patients with recent acute myocardial infarction and multivessel coronary disease. A total of 18,219 patients were randomized to receive either four weekly 6 g infusions of CSL112 or a placebo within five days of initial medical contact. Over 90, 180, and 365 days, the trial found no significant difference in the risk of myocardial infarction, stroke, or cardiovascular death between the two groups. Additionally, adverse events were similar across groups, though hypersensitivity was more common in the CSL112 group.

Reference (link to abstract – $ for full-text):

Michael Gibson et al. (2024). Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. New England Journal of Medicine. DOI: 10.1056/NEJMoa2400969.